BioStem Technologies, Inc.
BSEM
$4.02
$0.112.68%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -43.12% | -242.83% | 73.08% | 2,127.01% | 426.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.12% | -242.83% | 73.08% | 2,127.01% | 426.11% |
| Cost of Revenue | -71.58% | -81.72% | -61.64% | 447.07% | 1,203.81% |
| Gross Profit | -34.61% | -171.48% | 80.63% | 2,227.53% | 346.47% |
| SG&A Expenses | 33.76% | -86.21% | 85.07% | 1,830.89% | 17.33% |
| Depreciation & Amortization | 6.67% | 14.74% | 4.05% | 14.47% | -3.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.06% | -106.65% | 80.39% | 1,718.22% | 121.54% |
| Operating Income | -84.41% | -98.72% | 13.91% | 502.74% | 1,605.48% |
| Income Before Tax | -83.95% | -97.93% | 18.86% | 407.07% | 695.02% |
| Income Tax Expenses | -69.66% | -67.92% | -32.69% | -- | -- |
| Earnings from Continuing Operations | -88.84% | -108.98% | 37.61% | 666.13% | 543.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.84% | -108.98% | 37.61% | 666.13% | 543.37% |
| EBIT | -84.41% | -98.72% | 13.91% | 502.74% | 1,605.48% |
| EBITDA | -83.88% | -98.05% | 13.80% | -- | 1,745.71% |
| EPS Basic | -89.13% | -108.76% | 34.65% | 620.29% | 466.49% |
| Normalized Basic EPS | -84.36% | -97.97% | 16.27% | -- | 1,024.54% |
| EPS Diluted | -90.63% | -111.61% | 0.00% | 450.72% | 380.70% |
| Normalized Diluted EPS | -85.41% | -97.28% | -12.53% | -- | 814.25% |
| Average Basic Shares Outstanding | 2.60% | 2.53% | 2.19% | 8.79% | 20.94% |
| Average Diluted Shares Outstanding | 9.97% | -23.56% | 35.87% | 61.04% | 56.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |